Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™ seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™
image310
Vortexes are powerful and transformational centers of energy

BiotechVortex™

  

The BiotechVortex™ section of this site was created when I started seeing an increase in partnerships, mergers, and co-operative agreements, in both the biotech and medtech sectors. Here we will highlight these partnerships/agreements/mergers, even when no  specific products are identified.  

BiotechVortex™

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

image311

 

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

Thu April 2, 2020 8:00 AM|Business Wire|About: HZNP

-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment --

-- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)


 https://www.horizontherapeutics.com/ 


 https://www.horizontherapeutics.com/our-pipeline/ 


 https://www.businesswire.com/news/home/20200402005203/en/ 


 https://seekingalpha.com/symbol/HZNP 



Becton Dickinson, BioGX Get FDA Emergency Use Authorization For Rapid SARS-CoV-2 Test

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

image312

 

BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S.

Fri April 3, 2020 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX), a leading global medical technology company, and BioGX Inc.


 https://www.bd.com/en-us 


 http://biogx.com/ 


 https://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html 


 https://seekingalpha.com/symbol/BDX 


 http://biogx.com/news/becton-dickinson-biogx-get-fda-emergency-use-authorization-for-rapid-sars-cov-2-test 


 https://biogx.com/ 

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

image313

 

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Mon April 6, 2020 8:01 AM|GlobeNewswire|About: GSK, VIR

  • Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks

  • Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months

  • GSK to make equity investment of $250 million in Vir

LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. (VIR)


 https://www.vir.bio/ 


 https://www.vir.bio/science/#programs 


 https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus 


 https://seekingalpha.com/symbol/GSK 


 https://seekingalpha.com/symbol/VIR 

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

image314

 

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Mon April 6, 2020 6:15 AM|Business Wire|About: GILD

-- Multi-year, Multi-program Agreement Leverages Latest Insights of Microbiome --

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Second Genome


 https://www.businesswire.com/news/home/20200406005220/en/ 


 https://www.secondgenome.com/ 


 https://seekingalpha.com/symbol/GILD 


 https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery 

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

image315

 

Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

Mon April 6, 2020 7:00 AM|Business Wire|About: ALNY, DRNA

- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization -

- Companies Complete Non-Exclusive Intellectual Property Cross-License Agreement for the Development and Commercialization of Alnylam’s Lumasiran and Dicerna’s Nedosiran Investigational Programs for Primary Hyperoxaluria -

CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (DRNA) (Nasdaq: DRNA)


 https://www.alnylam.com/ 


 https://www.alnylam.com/alnylam-rnai-pipeline/ 


 https://seekingalpha.com/symbol/ALNY 


 https://dicerna.com/ 


 https://dicerna.com/pipeline/ 


 https://seekingalpha.com/symbol/DRNA 


 https://www.businesswire.com/news/home/20200406005200/en/ 


 Alpha-1 antitrypsin deficiency 

 https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency# 


 Primary hyperoxaluria 

 https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria 



Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

image316

BiotechVortex™

Generation Bio & Vir Biotechnology Collaborate on Scalable Non-Viral Gene Therapy Platform

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

image317

 

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

Mon March 30, 2020 7:00 AM|Business Wire|About: VIRQ4: 03-26-20 Earnings SummaryEPS of $-0.69 misses by $-0.06 Revenue of $0.98M (-% Y/Y) misses by $-1.59M

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Generation Bio and Vir Biotechnology (VIR) (Nasdaq: VIR) 


 https://www.businesswire.com/news/home/20200330005148/en/ 


 https://www.vir.bio/ 


 https://generationbio.com/ 


 https://seekingalpha.com/symbol/VIR 


 https://www.vir.bio/pipeline/ 



Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

 

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

Tue March 31, 2020 6:30 AM|PR Newswire|About: LLY

INDIANAPOLIS and OXFORD, England, March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an exclusive global licensing and research collaboration with Sitryx,


 https://www.prnewswire.com/news-releases/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines-301032137.html 


 http://www.sitryx.com/ 


 http://www.sitryx.com/news-and-events/press-releases/2020/ 


 https://seekingalpha.com/symbol/LLY 

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

image318

 

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Tue March 31, 2020 7:30 AM|Newsfile|About: NNVCNewsfile Corp

The Company's Update on its Development of COVID-19 Drug Candidate is Promising

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NNVC) (


 http://www.nanoviricides.com/ 


 http://www.nanoviricides.com/pipeline.html 


 https://smallcapsdaily.com/nanoviricides-the-latest-covid-19-drug-update-looks-promising/ 


 https://seekingalpha.com/symbol/NNVC 

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

image319

 

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

Tue March 31, 2020 2:00 PM|GlobeNewswire|About: SRNE

SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.


 https://sorrentotherapeutics.com/ 


 https://som.utmb.edu/ 


 Immuno-Oncology 

 https://sorrentotherapeutics.com/pipeline/ 


 https://seekingalpha.com/symbol/SRNE 

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

image320

 

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Tue March 31, 2020 4:05 PM|PR Newswire|About: RARE, RGNX

- Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO

PR Newswire

ROCKVILLE, Md. and NOVATO, Calif., March 31, 2020 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE),


 https://www.ultragenyx.com/ 


 https://www.regenxbio.com/ 


 https://www.ultragenyx.com/pipeline/ 


 https://www.regenxbio.com/therapeutic-programs/ 


 https://seekingalpha.com/symbol/RGNX 


 https://seekingalpha.com/symbol/RARE 



Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

image321

 

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

Tue March 31, 2020 4:05 PM|GlobeNewswire|About: EBS, NVAX

  • CDMO agreement for NanoFlu to support pathway to licensure
  • Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced an agreement with Novavax, Inc. (NVAX


 https://www.emergentbiosolutions.com/ 


 https://novavax.com/ 


 https://www.emergentbiosolutions.com/pipeline 


 https://novavax.com/page/8/vaccine-technology.html 


 https://seekingalpha.com/symbol/NVAX 


 https://seekingalpha.com/symbol/EBS 


 

NanoFlu – Nanoparticle Seasonal Influenza Vaccine - Older Adults (65+ yrs)

 https://novavax.com/page/11/clinical-stage-pipeline.html 

BiotechVortex™

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

 

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Tue March 24, 2020 9:32 AM|GlobeNewswire|About: SRNE

  • ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cycle
  • ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm’s 30,000 m2 cGMP facilities in China for human clinical trials and commercialization upon receipt of requisite regulatory approvals
  • Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK,


 https://sorrentotherapeutics.com/ 


 http://www.mabpharm.cn/en/index.php 


 https://sorrentotherapeutics.com/pipeline/ 


 https://seekingalpha.com/symbol/SRNE 


 https://apnews.com/Globe%20Newswire/5a08618b12f6f2f70ac2bc199b48324a 


 http://www.mabpharm.cn/en/research_product.php 

Multi-Lingual Support = Global MediXchange of Combating COVID-19 (GMCC)-Medical Personnel Worldwide

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

image322

 

Multi-Lingual Support From the Global MediXchange of Combating COVID-19 (GMCC) Programme to Further Enable Sharing Among Medical Personnel Worldwide

Wed March 25, 2020 11:43 PM|Business Wire|About: BABA

HANGZHOU, China--(BUSINESS WIRE)


 https://www.alibabacloud.com/solutions/dingtalk/international-medical-expert-communication-platform?spm=a3c0i.14157329.6596852130.2.1bf2772d5A46tB 


 

Resources Sharing Center

Fight COVID-19 without having to start from scratch

 https://covid-19.alibabacloud.com/#J_8102420620 


 

The Chinese Telemedicine Team
Is Here to Fight against COVID-19

International Medical Expert Communication Center
Is Officially Launched

 https://covid-19.alibabacloud.com/ 


 https://covid-19.alibabacloud.com/ 


 https://www.businesswire.com/news/home/20200325005799/en/ 


 https://seekingalpha.com/symbol/BABA 



Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

image323

 

Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Thu March 26, 2020 7:30 AM|GlobeNewswire|About: DVAXGlobeNewswire

EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX) (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI)


 https://www.dynavax.com/ 


 https://cepi.net/ 


 https://www.fda.gov/ 


 http://investors.dynavax.com/node/17866/pdf 


 https://seekingalpha.com/symbol/DVAX 


 http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-cepi-announce-collaboration-support-global-effort 



Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

image324

 

Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Fri March 27, 2020 2:00 AM|GlobeNewswire|About: SNY, TBIO

The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development

PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), and Translate Bio (TBIO)


 https://translate.bio/ 


 https://seekingalpha.com/symbol/SNY 


 https://seekingalpha.com/symbol/TBIO 


 https://www.sanofi.com/ 


 https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00 


 

Translate Bio Provides MRT5005 Program Updates

Thu March 26, 2020 4:30 PM|GlobeNewswire|About: TBIO

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –

 -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial operations; updated interim data readout timing to be provided at later date --

LEXINGTON, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio (TBIO)

 https://seekingalpha.com/pr/17820487-translate-bio-provides-mrt5005-program-updates 


 https://translate.bio/pipeline/ 

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

image325

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

image326

Medtronic Shares Ventilation Design Specifications to Accelerate Efforts to Increase Global Ventilator Production

Mon March 30, 2020 8:15 AM|GlobeNewswire|About: MDT

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) (NYSE:MDT)


 https://www.fda.gov/media/136318/download 


 https://www.medtronic.com/us-en/index.html 


 http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-shares-ventilation-design-specifications-accelerate 


 https://seekingalpha.com/symbol/MDT 

BiotechVortex™

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

image327

 

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

Fri March 13, 2020 9:41 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., March 13, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) 


 Cutting-edge technologies are the driving force behind our strong research and development pipeline 

 https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies 


 https://seekingalpha.com/symbol/JNJ 


 

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic

 https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine 


 https://www.jnj.com/coronavirus 


 https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat 

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

image328

 

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

Mon March 16, 2020 7:30 AM|PR Newswire|About: ACRX

Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction

Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative treatments to healthcare institutions

AcelRx and Tetraphase also enter into co-promotion agreement expected to generate significant commercial synergies immediately

Acquisition expected to close in Q2 2020

PR Newswire

REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX


 https://www.acelrx.com/ 


 https://www.tphase.com/# 


 https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals-301024578.html 


 https://www.tphase.com/products/xerava/ 


 https://seekingalpha.com/symbol/ACRX 



IDE196, a Protein Kinase C (PKC) inhibitor, and binimetinib, a MEK inhibitor

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

image329

 

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

Wed March 18, 2020 6:00 AM|PR Newswire|About: IDYA, PFEPR Newswire

SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (IDYA),


 https://www.prnewswire.com/news-releases/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-binimetinib-in-solid-tumors-harboring-gnaq-or-gna11-hotspot-mutations-301025907.html 


 https://www.ideayabio.com/ 


 https://seekingalpha.com/symbol/IDYA 


 https://seekingalpha.com/symbol/PFE 


 

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

 https://clinicaltrials.gov/ct2/show/NCT03947385?term=ideaya&draw=2&rank=1 






Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

 

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

Thu March 19, 2020 6:50 PM|PR Newswire|About: DHR, GE

WASHINGTON, March 19, 2020 /PRNewswire/ -- Danaher Corporation (DHR)


 https://www.danaher.com/ 


 https://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html 


 https://seekingalpha.com/symbol/DHR 

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

 

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Mon March 23, 2020 7:00 AM|GlobeNewswire|About: ACIU

  • CHF 10 million milestone recognizes development progress
  • Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation
  • Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

LAUSANNE, Switzerland, March 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU) (NASDAQ: ACIU)


 https://www.acimmune.com/ 


 https://www.lilly.com/ 


 https://ir.acimmune.com/news-releases/news-release-details/ac-immune-and-lilly-announce-license-and-collaboration-agreement?field_nir_news_date_value%5bmin%5d=2019 


 https://ir.acimmune.com/news-releases/news-release-details/ac-immune-initiates-phase-1-study-aci-3024-small-molecule-tau?field_nir_news_date_value%5bmin%5d=2019 


 https://seekingalpha.com/symbol/ACIU 


 https://seekingalpha.com/symbol/LLY 



Updates from Lilly about insulin supply and affordability

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

image330

BiotechVortex™

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

image331

 

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

Wed March 11, 2020 8:00 AM|GlobeNewswire|About: VIRGlobeNewswire

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology (VIR), Inc. (Nasdaq: VIR)


 https://www.vir.bio/ 


 https://seekingalpha.com/symbol/VIR 


 https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national 



Vir Biotechnology to Collaborate w Biogen on Manufacturing of Antibodies to Treat COVID-19

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

image332

 

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

03/12/20 at 8:00 AM EDTPDF Version

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB)


 

Vir Biotech up 27% premarket on COVID-19 deal with Biogen

Mar. 12, 2020 8:40 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: , SA News Editor 

 https://seekingalpha.com/news/3551009-vir-biotech-up-27-premarket-on-covidminus-19-deal-biogen 



Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

 

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Thu March 12, 2020 7:00 AM|PR Newswire|About: STRO

SOUTH SAN FRANCISCO, Calif., March 12, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO)


 https://www.sutrobio.com/ 


 https://www.prnewswire.com/news-releases/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck-301022013.html 


 https://seekingalpha.com/symbol/STRO 


 https://seekingalpha.com/symbol/MRK 



Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

image334

 

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Wed March 11, 2020 10:45 AM|GlobeNewswire|About: NVAX

  • Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University
  • Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX)


 https://www.who.int/publications-detail/world-malaria-report-2019 


 https://www.novavax.com/ 


 https://www.seruminstitute.com/ 


 https://www.novavax.com/page/11/clinical-stage-pipeline.html 


 https://seekingalpha.com/symbol/NVAX 

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

image335

 

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thu March 12, 2020 6:11 PM|PR Newswire|About: LLYPR Newswire

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (LLY)


 https://www.abcellera.com/ 


 https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment 


 https://www.lilly.com/ 


 https://www.prnewswire.com/news-releases/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19-301022689.html 


 https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment 


 https://seekingalpha.com/symbol/LLY 



BiotechVortex™

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

image336

 

CVS Kidney Care, Satellite Healthcare Enter Strategic Relationship to Advance the Care of Patients with Kidney Disease

Mon March 2, 2020 4:30 PM|PR Newswire|About: CVS

WOONSOCKET, R.I. and SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- CVS Kidney Care, a CVS Health (CVS) company, and Satellite Healthcare 


 https://www.cvshealth.com/ 


 https://www.satellitehealth.com/ 


 https://www.prnewswire.com/news-releases/cvs-kidney-care-satellite-healthcare-enter-strategic-relationship-to-advance-the-care-of-patients-with-kidney-disease-301014761.html 


 https://seekingalpha.com/symbol/CVS 



Thermo Fisher Scientific to Acquire QIAGEN N.V.

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

image337

 

Thermo Fisher Scientific to Acquire QIAGEN N.V.

Tue March 3, 2020 2:53 AM|PR Newswire|About: QGEN, TMO

- Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies

- Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close

PR Newswire

WALTHAM, Mass. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and QIAGEN N.V. (QGEN)


 https://www.thermofisher.com/us/en/home.html 


 https://www.qiagen.com/us/ 


 https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-qiagen-nv-301015072.html 


 https://seekingalpha.com/symbol/QGEN 


 https://seekingalpha.com/symbol/TMO 


 http://thermofisher.mediaroom.com/2020-03-03-Thermo-Fisher-Scientific-to-Acquire-QIAGEN-N-V,1 

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

image338

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

image339

 

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

Tue March 3, 2020 5:30 PM|Business Wire|About: BMY

NEW YORK & PARIS--(BUSINESS WIRE)-- Regulatory News:

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (BMY)


 http://www.voluntis.com/ 


 https://www.businesswire.com/news/home/20200303006062/en/ 


 https://news.bms.com/press-release/httpwwwvoluntiscomennewsnews-12020voluntis-and-bristol-myers-squibb-co-develop-digital 


 https://seekingalpha.com/symbol/BMY 



ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

image340

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

image341

 

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

Wed March 4, 2020 7:00 AM|Business Wire|About: ALNY, VIR

 — Recent Alnylam (ALNY) advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses

— Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option for 50-50 participation

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc.


 https://www.vir.bio/ 


 https://www.alnylam.com/ 


 https://www.businesswire.com/news/home/20200304005363/en/ 


 https://www.alnylam.com/alnylam-rnai-pipeline/ 


 https://seekingalpha.com/symbol/VIR 


 https://seekingalpha.com/symbol/ALNY 




BiotechVortex™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

image342

 

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Wed February 19, 2020 7:00 AM|Business Wire|About: DXCM, PODD

  • First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control
  • Initially compatible with Dexcom G6 CGM, with no fingersticks* required
  • Integration with the next generation Dexcom G7 CGM system, once available

SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)-- DexCom (DXCM), Inc. (NASDAQ: DXCM) and Insulet Corporation (PODD)


 http://www.insulet.com/ 


 https://www.myomnipod.com/home 


 https://www.businesswire.com/news/home/20200219005028/en/ 


 https://seekingalpha.com/symbol/DXCM 


 https://seekingalpha.com/symbol/PODD 

BMS-986249

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

image343

 

Bristol-Myers study expansions triggers $10M payment to CytomX

Feb. 24, 2020 8:16 AM ET|About: CytomX Therapeutics, Inc. (CTMX)|By: , SA News Editor 


 https://cytomx.com/ 


 https://cytomx.com/pipeline/ 


 https://seekingalpha.com/symbol/CTMX 



Heartline™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Takeda Acquires PvP Biologics

image344

 

Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke

Tue February 25, 2020 8:25 AM|PR Newswire|About: JNJ

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

PR Newswire

NEW BRUNSWICK, N.J., Feb. 25, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)


 https://www.heartline.com/ 


 

Johnson & Johnson Launches Heartline™, the First-of-Its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch can Help Reduce the Risk of Stroke

Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

Heart Health EducationPlay Video

New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ)

 https://www.multivu.com/players/English/8693251-heartline-study/ 


 https://www.jnj.com/ 


 https://www.prnewswire.com/news-releases/johnson--johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke-301010792.html 


 https://seekingalpha.com/symbol/JNJ 





Takeda Acquires PvP Biologics

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Takeda Acquires PvP Biologics

image345

 

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

Wed February 26, 2020 2:00 AM|Business Wire|About: TAK

− Investigational medicine TAK-062 is an oral computationally engineered super glutenase designed to improve the digestion of gluten

− Successful “build to buy” relationship adds second investigational therapy to Takeda’s pipeline for the potential treatment of uncontrolled celiac disease

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK


 

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

October 22, 2019 

 https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/ 


 https://www.takeda.com/ 


 https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes 


 https://www.businesswire.com/news/home/20200225005816/en/ 


 https://www.pvpbio.com/ 


 https://seekingalpha.com/symbol/TAK 



Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

image346

 

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Wed February 26, 2020 8:30 AM|GlobeNewswire|About: AMGN, CYTK

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Topline Results Expected in Q4 2020

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier


 https://www.amgen.com/ 


 https://cytokinetics.com/ 


 https://servier.com/en/ 



Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

image347

 

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Thu February 27, 2020 4:06 PM|Business Wire|About: BIIB, SGMO

  • Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
  • Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
  • Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
  • Biogen’s access to Sangamo's gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases

CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) and Sangamo Therapeutics, Inc. (SGMO),


 https://www.businesswire.com/news/home/20200227005961/en/ 


 

Sangamo and Biogen Neurology Collaboration

February 27, 2020

 https://investor.sangamo.com/static-files/81a67847-1710-4716-9e98-4fb798cbef8a 


 https://www.biogen.com/ 


 https://www.sangamo.com/ 


 https://seekingalpha.com/symbol/BIIB 


 https://seekingalpha.com/symbol/SGMO 



BiotechVortex™

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

image348

 

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Tue February 18, 2020 10:00 AM|GlobeNewswire|About: SNY

Sanofi (SNY) joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur,


 https://www.sanofi.com/ 


 https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00 


 https://seekingalpha.com/symbol/SNY 



J & J to expand Partnership w/ Dept. of Health & Human Services to Accelerate COVID-19 Treatments

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

image349

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

image350

 

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

Tue February 18, 2020 10:00 AM|Newsfile|About: JNJNewsfile Corp

San Diego, California--(Newsfile Corp. - February 18, 2020) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS, Shanghai


 http://www.dnxbio.com/index2.html 


 https://jlabs.jnjinnovation.com/quickfire-challenges/lung-cancer-innovation-quickfire-challenge 


 https://www.newsfilecorp.com/release/52493 

Takeda Canada = Investment in First Collaborative Canadian Lung Cancer Research Project w/ UHN

Takeda Canada = Investment in First Collaborative Canadian Lung Cancer Research Project w/ UHN

DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson

 

Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre

Tue February 4, 2020 2:34 PM|Canada Newswire|About: TAK

FOR CANADIAN AUDIENCES ONLY

Takeda Canada will invest $2.4 million in this important study which aims to evaluate real world outcomes in lung cancer patients

TORONTO, Feb. 4, 2020 /CNW/ - Takeda Canada Inc. is pleased to support the CAnadian CAncers with Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) - CARMA-BROS – in collaboration with Princess Margaret Cancer Centre, part of the University Health Network.


 https://seekingalpha.com/symbol/TKPHF 


 https://www.takeda.com/en-ca 



WuXi Biologics' - WuXi Vaccines = Vaccine Manufacturing Contract with a Global Vaccine Leader

Takeda Canada = Investment in First Collaborative Canadian Lung Cancer Research Project w/ UHN

WuXi Biologics' - WuXi Vaccines = Vaccine Manufacturing Contract with a Global Vaccine Leader

image351

 

WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

Tue February 18, 2020 5:42 AM|PR Newswire|About: WXXWY

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK)


 https://www.wuxibiologics.com/ 


 https://www.prnewswire.com/news-releases/wuxi-biologics-subsidiary-wuxi-vaccines-signed-long-term-vaccine-manufacturing-contract-with-a-global-vaccine-leader-301006453.html 


 https://seekingalpha.com/symbol/WXXWY 


 SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. 

 http://www.hile-bio.com/ 

Omnipod® Insulin Management System

Takeda Canada = Investment in First Collaborative Canadian Lung Cancer Research Project w/ UHN

WuXi Biologics' - WuXi Vaccines = Vaccine Manufacturing Contract with a Global Vaccine Leader

image352

 

Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care

Wed February 19, 2020 6:30 AM|PR Newswire|About: ABT, PODD

- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control

PR Newswire

ABBOTT PARK, Ill. and ACTON, Mass., Feb. 19, 2020 /PRNewswire/ -- Abbott (ABT) and Insulet Corporation (PODD)


 Nov 20, 2018

Insulet’s Omnipod DASH™ Insulin Management System Receives ISO 27001 Certification for Information Security

The Only Insulin Pump to Receive Both ISO 27001 and DTSec Certifications

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 20, 2018-- Insulet Corporation (NASDAQ: PODD)

 http://investor.insulet.com/news-releases/news-release-details/insulets-omnipod-dashtm-insulin-management-system-receives-iso 


 https://www.diabetestechnology.org/dtsec.shtml?ver=4 


 http://www.insulet.com/ 


 https://www.myomnipod.com/home 


 

FreeStyle Libre Indications and Important Safety Information

 https://www.freestylelibre.us/safety-information.html 


 https://www.abbott.com/ 


 https://www.prnewswire.com/news-releases/abbott-and-insulet-partner-to-integrate-next-generation-glucose-sensing-and-automated-insulin-delivery-technologies-for-seamless-diabetes-care-301007119.html 


 https://seekingalpha.com/symbol/PODD 


 https://seekingalpha.com/symbol/ABT